Cytokine-Treated Veto Cells Post-Transplant
Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant
What will happen during the trial?
Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Cytokine-treated veto cells may help the transplanted donor cells to develop and grow in recipients without causing graft-versus-host-disease (GVHD - when transplanted donor tissue attacks the tissues of the recipient's body).
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 48 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Allogeneic Stem Cell Transplant, Chemotherapy
- Trial Type
- Treatment
- Last Update
- 3 weeks ago
- SparkCures ID
- 1021
- NCT Identifier
- NCT03622788
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.